RxDoctor Payments Data

Roxanne Johnson

Family · Jamestown, NDNPI 1609912450

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.1% of the total across 165 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by AbbVie at 33.0% of the total. Among family clinicians in ND with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$2,530in general payments, 2019–2025

Across 165 payments — averaging $15.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$835
  • Neurocrine Biosciences, Inc.$323
  • Alkermes, Inc.$288
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$237
  • Otsuka America Pharmaceutical, Inc.$158
  • Teva Pharmaceuticals USA, Inc.$137
  • plus $552 from 9 others

What the payments were for

  • Food & beverage$2,48398%
  • Education$472%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,530 in reported general payments places this provider in the 90th percentile of 496 family providers in North Dakota.

See all family providers in North Dakota

Medicare billing

Part B allowed, 2024
$26,456
Medicare patients
57
Services billed
441

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CaplytaLumateperone Tosylate33$56,551
VraylarCariprazine Hcl41$52,498
LybalviOlanzapine/Samidorphan Malate25$40,139
RexultiBrexpiprazole18$25,451
Aripiprazole76$14,010
Clozapine48$7,578
Paliperidone ErPaliperidone20$4,615
Olanzapine43$3,269
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine38$1,013
Vilazodone Hcl13$942
Venlafaxine Hcl ErVenlafaxine Hcl53$826
Escitalopram Oxalate86$817
Prazosin Hcl31$691
Temazepam18$574
Quetiapine Fumarate51$561

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$237$56,55133 claims
AbbVieVraylar$835$52,49841 claims
Alkermes, Inc.Lybalvi$288$40,13925 claims
Otsuka America Pharmaceutical, Inc.Rexulti$158$25,45118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 496 family providers in North Dakota.

Other family in Jamestown

See the full list for North Dakota

Where these figures come from

Is this you, or does something look wrong? →